-- Competitive Grant Program to Offer Individual Grants of Up to
-- Application Period Open Until
This program aims to support a new generation of researchers working on some of the most pressing public health issues of our time. In its fifth year, the program will offer grants to early-career investigators who have demonstrated a commitment to helping people living with schizophrenia or bipolar disorder. The application period will run through
"We are committed to supporting research with the potential to create meaningful progress for those living with these complex and challenging diseases," said
The 5th annual Alkermes Pathways Research Awards program will offer grants in amounts of up to $100,000 per project. To qualify, early-career investigators must be M.D.s, Ph.D.s, or equivalent, who are within five years of their initial academic appointment or are current post-doctoral fellows, and who are affiliated with a medical or research institution within the
The Pathways program began in 2018 and has since provided funding to 21 researchers across
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham,
Alkermes Pathways Research Awards® is a registered service mark of Alkermes, Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors:
For Media: Katie Joyce +1 781 249 8927
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-launch-of-5th-annual-alkermes-pathways-research-awards-program-301634825.html
SOURCE